Funded Biotechnology Research Startups in United States
14 funded biotechnology research startups in united states — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
The 14 most recent funding rounds in U.S. biotechnology research span from November 2022 through April 2025, with disclosed amounts ranging from $50,000 (Walela, Chicago) to $50 million (Avidicure, South Holland, Illinois). The Boston-Cambridge corridor — home to Nanite, Empatica, Sensorium Therapeutics, and Concerto Biosciences — is the densest geographic cluster in this set, with California adding three more entries across San Francisco, San Diego, and Santa Clara.
Eight of the 14 rounds closed during November 2022 alone, including Sensorium Therapeutics' $30M Series A, Concerto Biosciences' $23M Series A, and Rebus Biosystems' $18M Series Unknown — all within an eight-day span. "Series Unknown" is the most frequent round classification, covering eight entries, which typically reflects private raises that lag in public disclosure. Activity in non-coastal markets such as Cincinnati, Houston, and Pittsburgh skews toward smaller, earlier-stage amounts.
Most recent rounds
14 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these 14 companies?
Avidicure's $50M Seed round (April 2025, South Holland, Illinois) is the largest, followed by Sensorium Therapeutics' $30M Series A (November 2022, Boston) and Concerto Biosciences' $23M Series A (November 2022, Cambridge, Massachusetts). Living Carbon's $21M Series A and Rebus Biosystems' $18M Series Unknown round out the top five by disclosed size.
Which cities have the heaviest concentration of biotechnology research funding activity in this dataset?
Boston and Cambridge, Massachusetts together account for four companies — Nanite, Empatica, Sensorium Therapeutics, and Concerto Biosciences — making the Greater Boston area the single densest cluster. California appears three times across San Francisco, San Diego, and Santa Clara, while Illinois has two entries (South Holland and Chicago).
What round stages appear most frequently?
"Series Unknown" is the dominant classification, covering eight of the 14 rows. Series A appears three times (Living Carbon, Sensorium Therapeutics, Concerto Biosciences), Seed twice (Avidicure, Nanite), and Series B once (Empatica, with an undisclosed amount).
Was there a concentrated window of funding activity in this segment?
Yes — eight of the 14 rounds closed in November 2022, with five of those landing between November 1 and November 8 alone: Walela, Concerto Biosciences, Rebus Biosystems, Sensorium Therapeutics, and The Citizen Science Lab. The dataset then thins out considerably before resuming with a handful of 2023 rounds and one 2024 entry.
How wide is the funding range across these companies?
Disclosed amounts span from $50,000 (Walela, Chicago, November 2022) to $50 million (Avidicure, South Holland, April 2025) — a 1,000x spread within the same segment. One round (Empatica's Series B) is undisclosed, and several "Series Unknown" raises in the $280K–$890K range suggest pre-institutional or angel-adjacent activity.
Are there funded biotechnology research startups outside traditional coastal biotech hubs?
Several appear in non-coastal markets: Orange Grove Bio (Cincinnati), FibroBiologics (Houston), Love Lifesciences (Overland Park, Kansas), The Citizen Science Lab (Pittsburgh), and Walela (Chicago). Disclosed amounts for these companies range from $50,000 to $5 million, well below the Boston and California entries that anchor the higher end of the dataset.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.